-
1.发明申请RAB6KIFL/KIF20A EPITOPE PEPTIDE AND VACCINES CONTAINING THE SAME 有权RAB6KIFL / KIF20A EPITOPE PEPTIDE和含有其的疫苗公开(公告)号：US20110262471A1
公开(公告)日：2011-10-27
申请号：US13125548
申请日：2009-10-15
IPC分类号： A61K39/00 , A61K38/16 , A61K31/7088 , C12N5/078 , A61P35/00 , C12N5/071 , C12N15/85 , C07K14/47 , C07H21/04
CPC分类号： A61K39/00 , A01K67/0278 , A01K2207/15 , A01K2217/052 , A01K2217/075 , A01K2217/15 , A01K2227/105 , A01K2267/03 , A01K2267/0387 , A61K38/16 , A61K39/0011 , A61K2039/5152 , A61K2039/5154 , A61K2039/5158 , A61K2039/55 , A61K2039/572 , A61K2039/585 , C07K14/47 , C07K14/4748 , C12N9/14 , C12N2799/027 , C12Y306/04004
摘要： The present invention provides oligopeptides comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 4 and 5. The present invention also provides a pharmaceutical composition containing the amino acid sequence of selected from the group consisting of SEQ ID NOs: 3, 4 and 5 formulated for the treatment or prevention of cancer in a subject. Furthermore, the present invention provides a method of inducing immune response using such oligopeptides and pharmaceutical agents.
摘要翻译： 本发明提供了包含选自SEQ ID NO：3,4和5的氨基酸序列的寡肽。本发明还提供含有选自SEQ ID NO：3,4和5的氨基酸序列的药物组合物。 3，4和5配制用于治疗或预防受试者的癌症。 此外，本发明提供使用这种寡肽和药剂诱导免疫应答的方法。
-
2.发明授权公开(公告)号：US08883966B2
公开(公告)日：2014-11-11
申请号：US13125548
申请日：2009-10-15
IPC分类号： A61K31/00 , A61K38/00 , A61K38/04 , C07K2/00 , C07K4/00 , C07K5/00 , C07K7/00 , C07K14/00 , C07K16/00 , C07K17/00 , G01N33/00 , G01N33/48 , A61K39/00 , C07K14/47 , C12N9/14
CPC分类号： A61K39/00 , A01K67/0278 , A01K2207/15 , A01K2217/052 , A01K2217/075 , A01K2217/15 , A01K2227/105 , A01K2267/03 , A01K2267/0387 , A61K38/16 , A61K39/0011 , A61K2039/5152 , A61K2039/5154 , A61K2039/5158 , A61K2039/55 , A61K2039/572 , A61K2039/585 , C07K14/47 , C07K14/4748 , C12N9/14 , C12N2799/027 , C12Y306/04004
摘要： The present invention provides oligopeptides comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 4 and 5. The present invention also provides a pharmaceutical composition containing the amino acid sequence of selected from the group consisting of SEQ ID NOs: 3, 4 and 5 formulated for the treatment or prevention of cancer in a subject. Furthermore, the present invention provides a method of inducing immune response using such oligopeptides and pharmaceutical agents.
摘要翻译： 本发明提供了包含选自SEQ ID NO：3,4和5的氨基酸序列的寡肽。本发明还提供含有选自SEQ ID NO：3,4和5的氨基酸序列的药物组合物。 3，4和5配制用于治疗或预防受试者的癌症。 此外，本发明提供使用这种寡肽和药剂诱导免疫应答的方法。
-
公开(公告)号：US08455444B2
公开(公告)日：2013-06-04
申请号：US12673451
申请日：2008-06-05
CPC分类号： A61K31/7088 , A61K38/00 , A61K39/0011 , C07K14/705
摘要： The present invention provides a peptide of the following (A) or (B): (A) a peptide including an amino acid sequence of SEQ ID NO: 1 or 2; (B) a peptide including an amino acid sequence of SEQ ID NO 1 or 2, wherein one, two, or several amino acid(s) are substituted, deleted, inserted, and/or added, and wherein the peptide has an activity to induce killer T cells.
摘要翻译： 本发明提供下述（A）或（B）的肽：（A）包含SEQ ID NO：1或2的氨基酸序列的肽; （B）包含SEQ ID NO 1或2的氨基酸序列的肽，其中一个，两个或几个氨基酸被取代，缺失，插入和/或加入，并且其中所述肽具有活性 诱导杀伤T细胞。
-
公开(公告)号：US20110165184A1
公开(公告)日：2011-07-07
申请号：US12673451
申请日：2008-06-05
CPC分类号： A61K31/7088 , A61K38/00 , A61K39/0011 , C07K14/705
摘要： The present invention provides a peptide of the following (A) or (B): (A) a peptide including an amino acid sequence of SEQ ID NO: 1 or 2; (B) a peptide including an amino acid sequence of SEQ ID NO 1 or 2, wherein one, two, or several amino acid(s) are substituted, deleted, inserted, and/or added, and wherein the peptide has an activity to induce killer T cells.
摘要翻译： 本发明提供下述（A）或（B）的肽：（A）包含SEQ ID NO：1或2的氨基酸序列的肽; （B）包含SEQ ID NO 1或2的氨基酸序列的肽，其中一个，两个或几个氨基酸被取代，缺失，插入和/或加入，并且其中所述肽具有活性 诱导杀伤T细胞。
-
公开(公告)号：US08598125B2
公开(公告)日：2013-12-03
申请号：US12673434
申请日：2008-06-13
IPC分类号： A61K38/00
CPC分类号： C12N5/0636 , A61K38/00 , A61K39/0011 , A61K2035/124 , A61K2039/5154 , C07K14/47 , C12N5/0639
摘要： The present invention provides the peptide of (A) or (B) below, and methods of using the peptide: (A) a peptide including the amino acid sequence of SEQ ID NO: 1 or 2, (B) a peptide which includes the amino acid sequence of SEQ ID NO: 1 or 2, wherein one, two, or several amino acid(s) are substituted, deleted, inserted, and/or added, and wherein the peptide shows killer T cell-inducing activity.
摘要翻译： 本发明提供下述（A）或（B）的肽，以及使用该肽的方法：（A）包含SEQ ID NO：1或2的氨基酸序列的肽，（B） SEQ ID NO：1或2的氨基酸序列，其中一个，两个或几个氨基酸被取代，缺失，插入和/或添加，并且其中所述肽显示杀伤T细胞诱导活性。
-
公开(公告)号：US20110152199A1
公开(公告)日：2011-06-23
申请号：US12673434
申请日：2008-06-13
CPC分类号： C12N5/0636 , A61K38/00 , A61K39/0011 , A61K2035/124 , A61K2039/5154 , C07K14/47 , C12N5/0639
摘要： The present invention provides the peptide of (A) or (B) below, and methods of using the peptide: (A) a peptide including the amino acid sequence of SEQ ID NO: 1 or 2, (B) a peptide which includes the amino acid sequence of SEQ ID NO: 1 or 2, wherein one, two, or several amino acid(s) are substituted, deleted, inserted, and/or added, and wherein the peptide shows killer T cell-inducing activity.
摘要翻译： 本发明提供下述（A）或（B）的肽，以及使用该肽的方法：（A）包含SEQ ID NO：1或2的氨基酸序列的肽，（B） SEQ ID NO：1或2的氨基酸序列，其中一个，两个或几个氨基酸被取代，缺失，插入和/或添加，并且其中所述肽显示杀伤T细胞诱导活性。
-
公开(公告)号：US08586547B2
公开(公告)日：2013-11-19
申请号：US13321812
申请日：2010-05-25
CPC分类号： C07K14/4748 , A61K39/0011 , A61K2039/5158
摘要： The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 18, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include one of the above mentioned amino acid sequences with substitution, deletion, or addition of one, two, or several amino acids sequences. The present invention also provides pharmaceutical compositions including these peptides. The peptides of the present invention can be used for treating cancer.
摘要翻译： 本发明提供分离的肽或衍生自SEQ ID NO：18的片段，其结合HLA抗原并诱导细胞毒性T淋巴细胞（CTL）。 肽可以包括一个上述氨基酸序列中的一个，两个或几个氨基酸序列的取代，缺失或添加。 本发明还提供包含这些肽的药物组合物。 本发明的肽可用于治疗癌症。
-
公开(公告)号：US20120164163A1
公开(公告)日：2012-06-28
申请号：US13321812
申请日：2010-05-25
IPC分类号： A61K39/00 , C12N5/10 , C12N5/02 , A61P37/02 , C12N1/21 , C07H21/04 , A61P35/00 , A61K38/10 , A61K38/08 , C07K7/08 , C07K7/06 , C07K16/00 , C12N5/00 , C12N15/63
CPC分类号： C07K14/4748 , A61K39/0011 , A61K2039/5158
摘要： The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 18, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include one of the above mentioned amino acid sequences with substitution, deletion, or addition of one, two, or several amino acids sequences. The present invention also provides pharmaceutical compositions including these peptides. The peptides of the present invention can be used for treating cancer.
摘要翻译： 本发明提供分离的肽或衍生自SEQ ID NO：18的片段，其结合HLA抗原并诱导细胞毒性T淋巴细胞（CTL）。 肽可以包括一个上述氨基酸序列中的一个，两个或几个氨基酸序列的取代，缺失或添加。 本发明还提供包含这些肽的药物组合物。 本发明的肽可用于治疗癌症。
-
公开(公告)号：US20110195081A1
公开(公告)日：2011-08-11
申请号：US12673432
申请日：2008-08-12
IPC分类号： A61K39/00 , C07K7/06 , C07H21/00 , C07K16/00 , C12N5/0783 , C12N15/00 , A61P35/00 , A61P37/04
CPC分类号： A61K39/0011 , A61K38/00 , A61K2039/57 , A61K2039/572 , A61K2039/585 , C07K7/06 , C07K7/08 , C12N5/0636 , C12N5/0638 , C12N2501/998 , C12N2502/11
摘要： An objective of the present invention is to provide a means for enabling cancer immunotherapy that targets approximately 30% of various cancer patients that highly express forkhead box M1 (FOXM1) among the Japanese, by identifying FOXM1-derived peptides that can activate cancer cell-damaging human killer T cells by binding to HLA-A2. The present invention provides a peptide of (A) or (B) below: (A) a peptide including the amino acid sequence of any one of SEQ ID NOs: 1 to 3; (B) a peptide which includes the amino acid sequence of any one of SEQ ID NOs: 1 to 3, wherein one, two, or several amino acid(s) are substituted, deleted, inserted, and/or added, and wherein the peptide shows cytotoxic (killer) T cell-inducing activity.
摘要翻译： 本发明的目的是提供一种能够通过鉴定可以激活癌细胞破坏性的FOXM1衍生的肽来靶向大约30％的高度表达日本人中的叉头盒M1（FOXM1）的各种癌症患者的癌症免疫治疗的手段 人类杀伤T细胞通过结合HLA-A2。 本发明提供下述（A）或（B）的肽：（A）包含SEQ ID NO：1〜3中任一项所述的氨基酸序列的肽; （B）包含SEQ ID NO：1至3中任一项的氨基酸序列的肽，其中一个，两个或几个氨基酸被取代，缺失，插入和/或添加，并且其中 肽显示出细胞毒性（杀伤）T细胞诱导活性。
-
公开(公告)号：US08569244B2
公开(公告)日：2013-10-29
申请号：US12673432
申请日：2008-08-12
IPC分类号： A61K38/00
CPC分类号： A61K39/0011 , A61K38/00 , A61K2039/57 , A61K2039/572 , A61K2039/585 , C07K7/06 , C07K7/08 , C12N5/0636 , C12N5/0638 , C12N2501/998 , C12N2502/11
摘要： An objective of the present invention is to provide a means for enabling cancer immunotherapy that targets approximately 30% of various cancer patients that highly express forkhead box M1 (FOXM1) among the Japanese, by identifying FOXM1-derived peptides that can activate cancer cell-damaging human killer T cells by binding to HLA-A2. The present invention provides a peptide of (A) or (B) below: (A) a peptide including the amino acid sequence of any one of SEQ ID NOs: 1 to 3; (B) a peptide which includes the amino acid sequence of any one of SEQ ID NOs: 1 to 3, wherein one, two, or several amino acid(s) are substituted, deleted, inserted, and/or added, and wherein the peptide shows cytotoxic (killer) T cell-inducing activity.
-
-
-
-
-
-
-
-
-
搜索结果
114 条记录 (耗时 0.027 秒)
